艾肯综合征与副甲状腺激素耐药性由于一种新的副甲状腺激素受体1型突变:临床特征和功能分析
Alistair D Calder1, Jeremy Allgrove2, Jakob Höppner3
1Radiology Department, Great Ormond Street Hospital for Children NHS Foundation Trust, London WC1N 3JH, United Kingdom.
概括
两个患有艾肯综合征的患者共享一种新的副甲状腺激素受体1型 (PTH1R) 变体,导致PTH抵抗和骨异常. 这一发现突出了PTH1RR的存在.
科学领域:
- 遗传学和分子生物学
- 内分泌学 在内分泌学.
- 骨发育不良症 骨发育不良症
背景情况:
- 艾肯综合征是一种罕见的骨发育不良.
- 副甲状腺激素抵抗会导致低血症和高血症.
- 通常,GNAS变种与伪偏偏甲状腺症有关.
研究的目的:
- 在两个患者中确定艾肯综合征的遗传原因.
- 为了研究新型PTH1R变异的功能后果.
- 为了阐明 PTH1R 在艾肯综合征发病过程中的作用.
主要方法:
- 整体外基因组测序以识别遗传变异.
- 在HEK293细胞中进行功能测试以评估受体活性.
- 对患者进行临床和生化评估.
主要成果:
- 在这两位患者中确定了一种新型同卵性PTH1R变体 (c.710T>A; p.Ile237Asn).
- 患者呈现了艾肯综合征的骨特征和临床PTH抵抗.
- 功能分析显示基底cAMP信号增加和突变PTH1Rs对PTH和PTHrP的反应减弱.
结论:
- 新的PTH1R变异在这些患者中是造成艾肯综合征的原因.
- 在PTH1R信号的变化有助于这种艾肯综合征亚型的发病.
- 这一发现扩大了艾肯综合征和PTH耐药性的已知遗传原因.
相关概念视频
The Parathyroid Glands
1.9K
The two pairs of parathyroid glands embedded within the posterior surface of the thyroid gland are restricted by a dense capsule around them. These glands comprise two distinct cell populations—parathyroid oxyphil and parathyroid principal cells- pivotal in calcium homeostasis.
Oxyphil cells, whose functions remain elusive, emerge during late puberty, adding a layer of complexity to the parathyroid gland's intricacies. In contrast, principal parathyroid cells undertake a vital role by...
Oxyphil cells, whose functions remain elusive, emerge during late puberty, adding a layer of complexity to the parathyroid gland's intricacies. In contrast, principal parathyroid cells undertake a vital role by...
1.9K
Transducer Mechanism: Enzyme-Linked Receptors
2.4K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.4K
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
141
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
141
Mitogens and the Cell Cycle
6.4K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K
Inborn Errors of Metabolism
145
Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
145
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
147
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
147


